DOCKET NO.: ISIS-0710

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Phillip Dan Cook et al.

Serial No.: 07/967,267

Group No.:

Filed: October 27, 1992

În re patent application of:

Examiner: G. Kunz

For:

Oligonucleotides Containing 2'-O-Modified Purines

I, Paul K. Legaard, Registration No. 38,534 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington,

Assistant Commissioner for Patents 20231 Washington, DC

RECEIVED

PATENT

UEU 1 5 1995

Sir:

## INFORMATION DISCLOSURE STATEMENT

GROUP 1800

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the aboveidentified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.
- (XX) In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of

Allowance under §1.311, therefore:

- (XX) Certification in Accordance with §1.97(e) is attached; or
- ( ) The fee of \$220.00 as set forth in \$1.17(p) is attached.
- ( ) In accordance with §1.97(d), this Information
  Disclosure Statement is being filed after the mailing
  date of either a Final Action under §1.113 or a Notice
  of Allowance under §1.311 but before the payment of the
  Issue Fee, therefore included are: Certification in
  Accordance with §1.97(e); Petition Requesting
  Consideration of the Information Disclosure Statement;
  and the fee of \$130.00 as set forth in §1.17(i)(1).
- (XX) Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in triplicate.

There are no listed references which are not in the English language.

Date: November 14, 1995

Signature

Paul K. Legaard

Registration No. 38,534

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100

NOV DOCKET NO.: ISIS-0710

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Phillip Dan Cook et al.

Serial No.: 07/967,267

Group No.: 1803

Filed: October 27, 1992

Examiner: G. Kunz

For:

Oligonucleotides Containing 2'-O-Modified Purines

 Paul K. Legaard, Registration No. 38,534 certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, Dec. 2021.

Paul K, Legaard Reg. No. 38/534

Assistant Commissioner for Patents Washington, DC 20231

Sir:

## CERTIFICATION UNDER 37 C.F.R. §1.97(e)

In accordance with 37 C.F.R. §1.97(e), certification is hereby made that:

- (XX) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.
- ( ) No item of information contained in the Information
  Disclosure Statement was cited in a communication from
  a foreign patent office in connection with a
  counterpart foreign application or, to the knowledge of
  the undersigned after making reasonable inquiry, was

known to any individual designated in §1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

Date: November 14, 1995

Signature

Paul K. Legaard

Registration No. 38,534

WOODCOCK WASHBURN KURTZ
MACKIEWICZ & NORRIS
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100